Business Context and Reporting Period
This Form 8-K is a current report filed by Ra Medical Systems, Inc. (not Catheter Precision, Inc.) on July 8, 2022. The registrant is a Delaware corporation with principal executive offices in Carlsbad, California, and its common stock trades on the NYSE American under the symbol RMED. The company is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Corporate Events
- Executive Appointment: The Board of Directors appointed Jonathan Will McGuire as Interim Chief Financial Officer, effective immediately on July 8, 2022. He will also serve as Principal Financial Officer and Principal Accounting Officer.
- Executive Departure: This appointment follows the resignation of Andrew Jackson as Chief Financial Officer, which became effective on May 25, 2022.
- Compensation: Mr. McGuire will not receive additional compensation for the interim CFO role, and no changes were made to his existing severance arrangements.
- Regulatory Milestone: On July 5, 2022, the Company received FDA 510(k) clearance for its DABRA 2.0 Catheter.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factor disclosures beyond the standard regulatory context. The appointment of an interim CFO addresses a leadership gap but does not indicate a change in the company's strategic direction based on this document alone.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) regarding the FDA 510(k) clearance for the DABRA 2.0 Catheter to understand commercial implications.
- Confirm the timeline for the search for a permanent Chief Financial Officer to replace the interim appointee.
- Review the Company's most recent 10-Q or 10-K for actual financial performance data, as this 8-K contains none.
- Check for any subsequent filings regarding the transition of the CFO role or further regulatory approvals.